A patient presents weeks or months after an aesthetic injectable procedure with swelling, tenderness or a new nodule.
What happens next should depend on what the practitioner believes is actually happening.
A delayed-onset nodule (DON) is not a diagnosis.
It can represent several different processes, from a non-inflammatory product-related nodule to a delayed immune-mediated reaction, granulomatous process, infection or abscess.
That distinction becomes particularly important when prescription medicines enter the management pathway.
The availability of an antibiotic, corticosteroid or another medicine should never determine the diagnosis.
Assessment comes first.
For prescribers, pharmacists and aesthetic practitioners, the critical questions are: What was injected? What is the likely pathology? Is infection reasonably suspected? Does the patient require investigation? Is a prescription medicine appropriate? Or does the patient need escalation rather than another prescription?
Emerging reports involving GLP-1/GIP weight-management medicines add another consideration to the patient’s medical history — but they do not change those fundamental principles.
What Is a Delayed-Onset Nodule?
A delayed-onset nodule is a lump, area of induration, swelling or inflammatory lesion appearing after the expected immediate post-procedure period.
DONs are frequently discussed in relation to dermal fillers, particularly hyaluronic acid, but delayed reactions shouldn’t automatically be viewed as an exclusively HA-filler phenomenon.
Depending on the injectable and presentation, the differential diagnosis can include:
- non-inflammatory product-related nodules;
- delayed inflammatory or immune-mediated reactions;
- granulomatous responses;
- infection;
- potentially biofilm-associated infection;
- abscess formation; and
- other local tissue responses.
The distinction matters because these conditions do not share one universal treatment pathway.
Delayed Nodules Are Not Confined to HA Dermal Filler
Aesthetic injectable history should extend beyond asking: “Have you had filler?”
Modern aesthetic practice involves multiple injectable categories, including:
- hyaluronic acid fillers;
- calcium hydroxylapatite;
- poly-L-lactic acid and other biostimulatory products; and
- botulinum toxin products.
This broader history has become particularly relevant following emerging case literature involving delayed nodules at different previous aesthetic injection sites, rather than a single filler product.
A 2026 JAAD Case Reports case described facial nodules at previous HA, calcium hydroxylapatite and incobotulinumtoxinA injection sites following initiation of compounded tirzepatide.
That is an unusual case and should not be generalised. But it demonstrates why clinicians investigating DONs need a complete injectable treatment history.
Start With the Clinical Assessment — Not the Prescription
When a patient presents with a delayed complication, it can be tempting to jump directly to treatment. That is particularly problematic where prescription medicines are involved.
Before considering pharmacological treatment, establish:
- what was injected;
- when it was injected;
- where it was injected;
- when symptoms appeared;
- whether symptoms are progressing;
- whether the lesion is inflammatory or non-inflammatory;
- whether infection is reasonably suspected;
- whether a collection or abscess may be present;
- what treatment has already been attempted; and
- what has changed in the patient’s medical or medication history.
The objective is to formulate an appropriate differential diagnosis before deciding whether medication is indicated.
Is the Nodule Inflammatory or Non-Inflammatory?
This is a fundamental distinction.
A small, painless, stable nodule presents differently from a lesion associated with significant erythema, warmth, pain, tenderness, progressive swelling, fluctuance, discharge, recurrent inflammation or systemic symptoms.
The presence of inflammatory features doesn’t automatically prove infection. But neither should significant inflammation automatically be labelled a sterile reaction.
The clinician needs to consider both possibilities.
When Should Infection Be Suspected?
Infection forms part of the recognised differential diagnosis of delayed aesthetic injectable complications.
Clinical concern may increase where the presentation includes increasing pain, warmth, progressive erythema, tenderness, significant oedema, fluctuance, purulent discharge, systemic symptoms or deterioration rather than improvement.
Where infection is suspected, appropriate investigation and escalation should be considered rather than treating the word “nodule” in isolation.
A Delayed Inflammatory Nodule Is Not Automatically a Biofilm
The term biofilm appears frequently in discussions of delayed filler complications. Biofilm-associated infection is a legitimate consideration, but it shouldn’t become a convenient diagnosis for every unexplained delayed inflammatory reaction.
Aesthetic practitioners and prescribers should distinguish between a suspected infectious process and a proven biofilm-associated infection. These aren’t interchangeable.
In the 2026 tirzepatide case, the authors acknowledged that infectious causes could not be completely excluded because the lesions were not biopsied. Their interpretation favoured an inflammatory process based on the clinical pattern.
That uncertainty is instructive. When evidence is incomplete, clinicians should describe the uncertainty rather than overstate the diagnosis.
What If an Abscess or Collection Is Suspected?
An abscess is not simply “an infection that needs stronger antibiotics.”
Where a collection is suspected, appropriate clinical assessment may indicate the need for imaging, drainage, microbiological sampling, culture and susceptibility testing where appropriate, antimicrobial therapy where clinically indicated and/or referral or specialist management.
The important principle is that prescribing medication alone may not provide source control where a drainable collection is present. That is why repeatedly prescribing medication without reconsidering the diagnosis can be problematic.
Where Can Ultrasound Help?
Ultrasound is increasingly used in aesthetic complication assessment.
Where available and appropriate, it may help clinicians determine where previously injected material is located, whether the lesion corresponds with the injected material, whether tissue characteristics suggest a different process, whether a fluid collection may be present and whether intervention or further investigation may be appropriate.
It isn’t necessary for every DON. But where the diagnosis is uncertain, the original injectable is unknown or an abscess is suspected, additional information can materially change the management pathway.
Antibiotics: Treat Infection, Not the Word “Nodule”
Antibiotics can be appropriate where bacterial infection is clinically suspected or established. But a delayed-onset nodule alone is not an indication for antibiotics.
Unnecessary antibiotic use exposes patients to adverse effects and contributes to antimicrobial resistance.
Equally, where genuine infection is suspected, treatment should not be delayed merely because delayed inflammatory filler reactions can also be sterile.
Antimicrobial decisions should take account of the suspected site and nature of infection, severity, patient-specific factors, relevant microbiological information and current clinical guidance.
Prescription-only medicines should be prescribed following an appropriate assessment by an authorised prescriber.
Why Repeated Empirical Antibiotics Can Be a Warning Sign
A patient may occasionally arrive after already receiving several treatment courses elsewhere.
If symptoms persist despite apparently appropriate management, the response shouldn’t automatically be: “Try another antibiotic.” Reassessment may be more important.
Questions include: Is the original diagnosis correct? Is infection actually present? Could a collection require drainage? Has microbiology been obtained where appropriate? Is an injected material contributing? Is there a non-infectious inflammatory process? Is specialist input required?
Treatment failure is information. It should prompt reconsideration of the diagnosis rather than indefinite repetition of the same strategy.
What About Corticosteroids?
Corticosteroids may have a role in selected inflammatory complications following appropriate clinical assessment.
However, suppressing inflammation without adequately considering infection may be inappropriate and potentially harmful.
The clinician needs to understand why it is inflamed. This is another reason DON management requires a differential diagnosis rather than a universal treatment protocol.
Where Does Hyaluronidase Fit?
Hyaluronidase isn’t an antibiotic or anti-inflammatory medicine, but it is highly relevant to DON management involving HA filler.
It can degrade hyaluronic acid and may form part of the management of selected HA-related complications.
Is the injectable actually HA? Hyaluronidase doesn’t simply dissolve CaHA or PLLA.
Is infection suspected? The wider clinical presentation needs to be considered.
Is there a collection? Further investigation or intervention may be necessary.
Is the diagnosis clear? The availability of hyaluronidase should not substitute for assessment.
The broader principle remains: identify the likely pathology before selecting the intervention.
Antimicrobial Stewardship Matters in Aesthetic Medicine
Aesthetic complications don’t sit outside normal principles of responsible prescribing.
Antimicrobial stewardship remains important. That means avoiding unnecessary antibiotic exposure while ensuring patients with genuine infection receive appropriate treatment.
Prescribers should be able to justify why an antimicrobial is required, the suspected infection being treated, why the selected medicine is appropriate, duration and review arrangements, what happens if the patient deteriorates and when investigation or referral is necessary.
This is particularly important in a sector where complications may sometimes be assessed remotely or by a clinician who did not perform the original procedure.
Prescribing for an Aesthetic Complication Requires a Proper Clinical Pathway
A prescription should be the consequence of a clinical decision. It should not be a transactional mechanism for obtaining a medicine.
Where a prescription-only medicine is required, the prescriber needs sufficient information to make an appropriate prescribing decision.
Practitioners can read more about the wider UK prescribing framework in Who Can Prescribe Botulinum Toxin in the UK? and Patient Specific Directions (PSDs) in Aesthetics.
For common pitfalls involving aesthetic prescriptions, see Aesthetic Prescription Errors: 9 Common Mistakes That Delay Dispensing.
These resources address different prescribing questions, but the underlying principle is the same: prescription medicines require appropriate clinical governance.
What Has Changed Since the Injectable Treatment?
A delayed complication requires a new medical history. Don’t rely solely on the consultation completed when the original aesthetic procedure occurred.
Since treatment, the patient may have developed an infection, experienced systemic illness, undergone dental treatment, received a vaccination, started a new medicine, changed the dose of an existing medicine or developed another medical condition.
This can be clinically relevant when investigating a delayed reaction.
Where Do GLP-1/GIP Medicines Fit?
GLP-1/GIP medicines are an emerging part of the history, not a diagnosis for DONs.
The 2026 JAAD Case Reports publication involving compounded tirzepatide described nodules developing at previous HA, CaHA and incobotulinumtoxinA injection sites.
The reported pattern included cessation of new nodules after discontinuation and recurrence following rechallenge and dose escalation.
That makes the temporal association noteworthy. It doesn’t establish that tirzepatide caused the nodules.
Important limitations included the compounded nature of the product and incomplete ability to exclude other explanations.
The appropriate clinical takeaway isn’t: “Tirzepatide causes delayed aesthetic nodules.” It’s: “Ask about newly commenced and recently changed medicines when assessing an unexplained delayed reaction.”
What About Semaglutide?
Published literature has also discussed delayed inflammatory reactions involving previous HA filler in the context of semaglutide.
Again, this is emerging evidence. It doesn’t establish incidence, causation or a GLP-1 class effect. It does support obtaining a complete medication history.
Should a Patient Stop Their GLP-1/GIP Medicine?
Not automatically.
Aesthetic practitioners shouldn’t independently advise a patient to discontinue prescribed semaglutide, tirzepatide or another medicine solely because a DON has appeared.
Medication decisions should involve the clinician responsible for prescribing and monitoring the patient’s treatment, alongside those assessing the complication.
For a deeper examination of this issue from the weight-management perspective, read GLP-1 Weight-Loss Treatment and Previous Dermal Filler: What We’ve Seen in Clinical Practice.
The Aesthetic Injectable Perspective
For practitioners wanting a broader examination of DONs across HA filler, CaHA, biostimulatory injectables and previous toxin injection sites, read Delayed-Onset Nodules After Aesthetic Injectables: A Practitioner Guide.
This Longeva Pharma article deliberately focuses on a different question: when a DON may require prescription medicines, investigation or escalation, what does responsible medicines management look like?
When Should the Patient Be Escalated?
Escalation or specialist input should be considered where infection or abscess is suspected; systemic illness is present; symptoms are severe or rapidly progressing; the diagnosis remains uncertain; the injected material is unknown; several injectable products may be involved; imaging is required; microbiological investigation may change management; previous treatment has failed; or the presentation exceeds the practitioner’s competence.
A prescription should never be used to postpone a referral that the patient actually needs.
A Medicines-Focused DON Assessment Framework
1. Establish the injectable history
HA, CaHA, PLLA, toxin or another product?
2. Establish the chronology
When was treatment performed and when did symptoms develop?
3. Examine the lesion
Inflammatory or non-inflammatory?
4. Assess for infection
Pain, heat, erythema, swelling, fluctuance, discharge or systemic symptoms?
5. Consider an abscess or collection
Would imaging or drainage need to be considered?
6. Update the medical history
What has happened since the aesthetic treatment?
7. Update the medication history
New medicines? Dose changes? GLP-1/GIP treatment?
8. Consider investigation
Would ultrasound or microbiology materially change the decision?
9. Decide whether medication is actually indicated
Don’t prescribe simply because a medicine is available.
10. Prescribe appropriately
Where a POM is indicated, prescribing must follow appropriate clinical assessment by an authorised prescriber.
11. Review the response
Failure to improve should trigger reassessment.
12. Escalate where necessary
Recognise when another clinician or service needs to take over.
The Key Message for Prescribers and Aesthetic Practitioners
A delayed-onset nodule is not an antibiotic diagnosis. It isn’t a corticosteroid diagnosis. It isn’t automatically a hyaluronidase diagnosis. And it isn’t a GLP-1 diagnosis.
It is a clinical presentation requiring the practitioner to determine what may be happening underneath.
The correct sequence is: history → examination → differential diagnosis → investigation where appropriate → treatment decision → review → escalation where necessary.
Emerging GLP-1/GIP evidence adds another potentially relevant question to the patient’s history. It doesn’t replace the established principles of complication assessment.
And where prescription medicines become necessary, good aesthetic complication management becomes good medicines management too.
Treat the patient and suspected pathology — not simply the word “nodule”.
References and Further Reading
- Moore LC, Hurley K, Moore AY. Facial nodules following filler injections after initiating compounded tirzepatide use. JAAD Case Reports. 2026;72:1–3. doi:10.1016/j.jdcr.2026.03.042.
- Moore LC, Hurley K, Moore AY. Inflammation-mediated facial nodules to compounded tirzepatide. JAAD Case Reports. 2026;75:215. doi:10.1016/j.jdcr.2026.06.026.
- Artzi O, et al. Delayed inflammatory reactions to hyaluronic acid fillers: a literature review and proposed treatment algorithm. Clinical, Cosmetic and Investigational Dermatology. 2020;13:371–378.
- U.S. Food and Drug Administration. Dermal Fillers (Soft Tissue Fillers). Safety information concerning dermal filler complications and inflammatory reactions.
- Practitioners should also refer to current UK antimicrobial, prescribing and professional guidance applicable to the individual clinical presentation.
Professional disclaimer: This article is intended for educational information for healthcare and aesthetic professionals. It does not provide an individual treatment protocol and does not replace clinical assessment, diagnosis, prescribing judgement, microbiological investigation or specialist advice. The emerging literature does not establish that semaglutide, tirzepatide or other GLP-1/GIP medicines cause delayed-onset nodules. Prescription-only medicines should only be prescribed following an appropriate assessment by an authorised prescriber.